[Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study]

Clin Ter. 2011;162(4):331-41.
[Article in Italian]

Abstract

Introduction: The present study aims to evaluate effectiveness of antipsychotics in a cohort of chronic outpatients affected by schizophrenia and related disorders.

Materials and methods: Three hundred chronic patients affected by schizophrenia (n=173), schizoaffective (n=117) and delusional (n=60) disorder who were in treament with antipsychotics on 1.3.2008 were considered in the study; effectiveness of antipsychotic treatment was evaluated by means of rates of all cause discontinuation in a 12 months period (31.3.2008-31.3.2009) and of "overall duration of treatment" (DT) (duration of treatment retrospectively evaluated on the basis of clinical records+duration of treatment prospectively evaluated during the 12-months follow up).

Results: Discontinuation of treatment was registered in 25% of patients (29% due to side effects, 14% due to scarce adherence, 11% due to lack of efficacy, 22% due to more causes). Clozapine (7%), Risperidon Long-acting (10%), Typical Antipsychotics depot (11%) and Olanzapine were associated to lower rates of all causes discontinuation. Overall mean duration of antipsychotic treatment was 18± 32 months, with statistically significant differences between drugs (F=4.65, p=0.000). Clozapine (65 mo), Olanzapine (50 mo), butyrophenones (49 mo), typical antipsychotics depot (48 mo), and risperidone (47.5 mo) were the antipsychotics with a longer duration of treatment. Only Clozapine showed a significantly longer DT than any other antipsychotic medication excluding buthyrrohenones.

Conclusions: Rates of all cause discontinuation of antipsychotics appear to be somewhat lower than expected on the basis of pragmatic studied published in the last years; similarly overall duration of treatment seems to be longer. Clozapine is associated to a higher overall effectiveness respect to any other atypical antipsychotic.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines / administration & dosage
  • Benzodiazepines / adverse effects
  • Benzodiazepines / therapeutic use
  • Butyrophenones / administration & dosage
  • Butyrophenones / adverse effects
  • Butyrophenones / therapeutic use
  • Clozapine / administration & dosage
  • Clozapine / adverse effects
  • Clozapine / therapeutic use
  • Delayed-Action Preparations
  • Delusions / drug therapy*
  • Dibenzothiazepines / administration & dosage
  • Dibenzothiazepines / adverse effects
  • Dibenzothiazepines / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Middle Aged
  • Olanzapine
  • Patient Dropouts
  • Prospective Studies
  • Psychotic Disorders / drug therapy*
  • Quetiapine Fumarate
  • Retrospective Studies
  • Risperidone / administration & dosage
  • Risperidone / adverse effects
  • Risperidone / therapeutic use
  • Schizophrenia / drug therapy*
  • Young Adult

Substances

  • Antipsychotic Agents
  • Butyrophenones
  • Delayed-Action Preparations
  • Dibenzothiazepines
  • Benzodiazepines
  • Quetiapine Fumarate
  • Clozapine
  • Risperidone
  • Olanzapine